Actualités Point Loma Resources Ltd - PLX | Actions TSX Venture Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

CARMIEL, Israel, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that Yossi Maimon...

Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

CARMIEL, Israel, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Yossi Maimon, the...

European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

NEW YORK and CARMIEL, Israel, Nov. 1, 2012 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX...

Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli

CARMIEL, Israel, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that is has...

Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference

CARMIEL, Israel, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), announced today that Dr. David Aviezer...

Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102, a Mo

CARMIEL, Israel, Aug. 13, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that it has received...

Protalix BioTherapeutics to Present at the Canaccord Genuity 32nd Annual Growth Conference

CARMIEL, Israel, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX) announced today that Yossi Maimon, the...

Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium

CARMIEL, Israel, Feb. 11 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that additional data from...

Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network

CARMIEL, Israel, Feb. 4 /PRNewswire-FirstCall/ -- Protalix Biotherapeutics, Inc. (NYSE- Amex: PLX) today announced that data from its pivotal...

Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease

CARMIEL, Israel, Feb. 2 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (NYSE Amex: PLX) announced today that, in connection with the...

European Medicines Agency's COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix's taliglucerase alfa

CARMIEL, Israel, Jan. 13 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that the Committee for Orphan...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Point Loma Resources Ltd (PLX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

PLX Actualités

Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli

Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference

Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102, a Mo

Protalix BioTherapeutics to Present at the Canaccord Genuity 32nd Annual Growth Conference

Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium

Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network

Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease

European Medicines Agency's COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix's taliglucerase alfa

Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs

American Stock Exchange Lists Common Stock of Protalix BioTherapeutics, Inc.

Affiliates of Ramius Capital Send Letter to Board of Directors of Plains Resources Inc.

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Point Loma Resources Ltd (PLX) Actualités

Point Loma Resources Ltd (PLX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

PLX Actualités

Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

Protalix BioTherapeutics Receives Marketing Authorization for Elelyso(TM) for the Treatment of Gaucher Disease From the Israeli

Protalix BioTherapeutics to Present at the UBS Global Life Sciences Conference

Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102, a Mo

Protalix BioTherapeutics to Present at the Canaccord Genuity 32nd Annual Growth Conference

Protalix Presents Additional Phase III Data for taliglucerase alfa at the WORLD Symposium

Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network

Protalix Announces NDA Submission Update for taliglucerase alfa for the Treatment of Gaucher Disease

European Medicines Agency's COMP Adopts Positive Opinion for the Orphan Drug Designation for Protalix's taliglucerase alfa

Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs

American Stock Exchange Lists Common Stock of Protalix BioTherapeutics, Inc.

Affiliates of Ramius Capital Send Letter to Board of Directors of Plains Resources Inc.

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application